Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07629999 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Not yet
- Registry status
- Phase 1
- Development phase
- 118
- Enrollment target
NCT07629999 is a Phase 1 study that has not yet begun recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 118 participants.
The verdict
NCT07629999, a Phase 1 study, has not yet begun recruiting, sponsored by Bristol-Myers Squibb.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 118 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of BMS-986533 in healthy participants receiving single and multiple doses, to assess food and pH effects on the relative bioavailability of BMS-986533, and the P-gp and BCRP-mediated drug-drug interaction potential of the study drug
Interventions
- DRUG Placebo
- DRUG Rosuvastatin
- DRUG Famotidine
- DRUG Dabigatran Etexilate
- DRUG BMS-986533
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07629999
The ClinicalTrials.gov registry entry for NCT07629999 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT07629999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07629999 about?
NCT07629999 is a clinical study titled "Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants". The purpose of this study is to evaluate the safety and pharmacokinetics of BMS-986533 in healthy participants receiving single and multiple doses, to assess food and pH effects on the relative bioavailability of BMS-986533, and the P-gp and BCRP-mediated drug-drug interaction potential of the study...
What is the current status of trial NCT07629999?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 118 participants. The study started on 2026-06-30. Estimated completion is 2027-06-01.
What interventions are being tested in trial NCT07629999?
The interventions under investigation include: Placebo (DRUG), Rosuvastatin (DRUG), Famotidine (DRUG), Dabigatran Etexilate (DRUG), BMS-986533 (DRUG).
Who is sponsoring clinical trial NCT07629999?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.